FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020825132> ?p ?o ?g. }

• W2020825132 endingPage "339" @default.
• W2020825132 startingPage "326" @default.
• W2020825132 abstract "Four Venezuelan patients with the autosomal recessive Chediak-Higashi syndrome (CHS) were studied. The results confirm the severe reduction in natural killer (NK) cell activity, as previously described and showed also a decline in the activity of cells involved in antibody-dependent cellular cytotoxicity (ADCC). No defect was found in the production of immunoglobulins and of specific antibodies to measles, varicella, herpes simplex, and cytomegalo viruses. Two of the patients had extremely high antibody titers to the Epstein-Barr virus (EBV) specific viral capsid antigen (VCA), to the restricted (R) component of the EBV-induced early antigen complex, and to the EBV-associated nuclear antigen (EBNA). These two patients had enlarged livers, spleens, and lymph nodes indicative of the lymphoproliferative phase. The other two patients were initially negative for all EBV-associated antibodies but seroconverted subsequently and, in the course of a year, also developed high antibody titers to VCA and R. In one of these patients the primary infection was accompanied by moderate signs of infectious mononucleosis (IM) followed after more than 6 months by persistent hepatosplenomegaly. The other patient also developed signs of a lymphoproliferative syndrome with hepatosplenomegaly and jaundice and died 8 months later. Such high anti-R titers are seen frequently in Burkitt's lymphoma, but rarely in other conditions. It is likely that the high antibody titers reflect an increased production of VCA and R due to defective NK and ADCC cell activities so that productively infected B lymphocytes are no longer eliminated before they have synthesized maximal amounts of antigens. The high anti-EBNA titers suggest normal T lymphocyte function. The possibility that the accelerated, lymphoma-like phase of the CHS involves EBV-transformed cells is discussed." @default.
• W2020825132 created "2016-06-24" @default.
• W2020825132 creator A5008827638 @default.
• W2020825132 creator A5015731703 @default.
• W2020825132 creator A5028019045 @default.
• W2020825132 creator A5036804587 @default.
• W2020825132 creator A5038323760 @default.
• W2020825132 creator A5051391047 @default.
• W2020825132 date "1983-06-01" @default.
• W2020825132 modified "2023-10-02" @default.
• W2020825132 title "Elevated antibody titers to Epstein-Barr virus and low natural killer cell activity in patients with Chediak-Higashi syndrome" @default.
• W2020825132 cites W142229570 @default.
• W2020825132 cites W1545599844 @default.
• W2020825132 cites W1963463669 @default.
• W2020825132 cites W1965011982 @default.
• W2020825132 cites W1965481766 @default.
• W2020825132 cites W1968634466 @default.
• W2020825132 cites W1970748912 @default.
• W2020825132 cites W1970848880 @default.
• W2020825132 cites W1974898599 @default.
• W2020825132 cites W1984564944 @default.
• W2020825132 cites W1990673601 @default.
• W2020825132 cites W1998322123 @default.
• W2020825132 cites W1999127816 @default.
• W2020825132 cites W1999237928 @default.
• W2020825132 cites W2009011904 @default.
• W2020825132 cites W2010599722 @default.
• W2020825132 cites W2015052084 @default.
• W2020825132 cites W2025841186 @default.
• W2020825132 cites W2027611582 @default.
• W2020825132 cites W2031224007 @default.
• W2020825132 cites W2037554647 @default.
• W2020825132 cites W2042081963 @default.
• W2020825132 cites W2058841383 @default.
• W2020825132 cites W2070149310 @default.
• W2020825132 cites W2074403327 @default.
• W2020825132 cites W2084093106 @default.
• W2020825132 cites W2087708213 @default.
• W2020825132 cites W2094668768 @default.
• W2020825132 cites W2106863580 @default.
• W2020825132 cites W2124510736 @default.
• W2020825132 cites W2133166743 @default.
• W2020825132 cites W2144397761 @default.
• W2020825132 cites W2315608135 @default.
• W2020825132 cites W4239139991 @default.
• W2020825132 cites W4251824554 @default.
• W2020825132 cites W2020299533 @default.
• W2020825132 doi "https://doi.org/10.1016/0090-1229(83)90085-5" @default.
• W2020825132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6307571" @default.
• W2020825132 hasPublicationYear "1983" @default.
• W2020825132 type Work @default.
• W2020825132 sameAs 2020825132 @default.
• W2020825132 citedByCount "43" @default.
• W2020825132 countsByYear W20208251322014 @default.
• W2020825132 countsByYear W20208251322015 @default.
• W2020825132 countsByYear W20208251322022 @default.
• W2020825132 countsByYear W20208251322023 @default.
• W2020825132 crossrefType "journal-article" @default.
• W2020825132 hasAuthorship W2020825132A5008827638 @default.
• W2020825132 hasAuthorship W2020825132A5015731703 @default.
• W2020825132 hasAuthorship W2020825132A5028019045 @default.
• W2020825132 hasAuthorship W2020825132A5036804587 @default.
• W2020825132 hasAuthorship W2020825132A5038323760 @default.
• W2020825132 hasAuthorship W2020825132A5051391047 @default.
• W2020825132 hasConcept C142724271 @default.
• W2020825132 hasConcept C147483822 @default.
• W2020825132 hasConcept C159047783 @default.
• W2020825132 hasConcept C159654299 @default.
• W2020825132 hasConcept C203014093 @default.
• W2020825132 hasConcept C22889606 @default.
• W2020825132 hasConcept C2522874641 @default.
• W2020825132 hasConcept C2776129502 @default.
• W2020825132 hasConcept C2779134260 @default.
• W2020825132 hasConcept C2779440204 @default.
• W2020825132 hasConcept C2781375147 @default.
• W2020825132 hasConcept C32611913 @default.
• W2020825132 hasConcept C40677261 @default.
• W2020825132 hasConcept C542903549 @default.
• W2020825132 hasConcept C71924100 @default.
• W2020825132 hasConcept C86803240 @default.
• W2020825132 hasConceptScore W2020825132C142724271 @default.
• W2020825132 hasConceptScore W2020825132C147483822 @default.
• W2020825132 hasConceptScore W2020825132C159047783 @default.
• W2020825132 hasConceptScore W2020825132C159654299 @default.
• W2020825132 hasConceptScore W2020825132C203014093 @default.
• W2020825132 hasConceptScore W2020825132C22889606 @default.
• W2020825132 hasConceptScore W2020825132C2522874641 @default.
• W2020825132 hasConceptScore W2020825132C2776129502 @default.
• W2020825132 hasConceptScore W2020825132C2779134260 @default.
• W2020825132 hasConceptScore W2020825132C2779440204 @default.
• W2020825132 hasConceptScore W2020825132C2781375147 @default.
• W2020825132 hasConceptScore W2020825132C32611913 @default.
• W2020825132 hasConceptScore W2020825132C40677261 @default.
• W2020825132 hasConceptScore W2020825132C542903549 @default.
• W2020825132 hasConceptScore W2020825132C71924100 @default.
• W2020825132 hasConceptScore W2020825132C86803240 @default.
• W2020825132 hasIssue "3" @default.
• W2020825132 hasLocation W20208251321 @default.

• next